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The use of Complementary and Alternative Medicine (CAM;補充與替代醫學 bǔ chong yǔ tì dai yı xue) has
been rapidly increasing among cancer patients. However, this pervasiveness is still largely unexplored
among Malaysian cancer patients. The current study aimed to evaluate the patterns of CAM use among
cancer patients from a local hospital in Malaysia. In addition, the study focused on the information-
seeking behavior and CAM use disclosure to doctors. Of 393 patients, 184 (46.1%) had used CAM for
their cancers. CAM usage was signiﬁcantly associated with gender (p ¼ 0.021), level of education
(p ¼ 0.001), employment status (p ¼ 0.02), and monthly income (p < 0.001). Among frequently used CAM
were nutritional supplements (n ¼ 77, 41.8%), natural products (n ¼ 74, 40.2%), and multivitamin (n ¼ 62,
33.6%). Friends and family members were the most common source of CAM information (n ¼ 139, 75.5%).
Seventy-nine (43%) reported to disclose their CAM use to the health care providers. The most common
(n ¼ 63, 34.2%) reason of nondisclosure was “it is not important to discuss it with oncologist.” This study
conﬁrmed that CAM use is common among Malaysian cancer patients, thus highlighting a greater need
for patient education regarding CAM therapies and their potential interactions with conventional ther-
apies. Although some types of CAM therapies may help patients to cope with emotional distress and
improve quality of life, CAM, with no proven efﬁcacy, may pose dangers to patients' health due to in-
teractions with conventional therapies. Doctors and other health care providers including nurses and
pharmacists should engage cancer patients in an open nonjudgmental dialog to ascertain CAM use
disclosure to their health care providers.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In Malaysia, use of Complementary and Alternative Medicine
(CAM; 補充與替代醫學 bǔ chong yǔ tì dai yı xue) for health main-
tenance, disease prevention and treatment is prevalent among
healthy individuals as well as patients with chronic diseases.1,2
Particular to cancer, numerous studies reported a signiﬁcantly
high degree of CAM use among the Malaysian population.3,4 At thersiti Teknologi MARA (UiTM),
nang, Malaysia.
(M. Farooqui).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).same time approximately 80% of the population in African and
Asian countries reported CAM as a primary source to cure and
prevent disease.5 The cumulative incidence rate of CAM use among
cancer patients is in the wide range of 14.5e91%.6,7 The wide
variation is often due to a lack of agreement on deﬁnition and di-
mensions of CAM.8 The National Centre of CAM deﬁnes CAM as “a
group of diverse medical and healthcare systems, practices, and
products that are not currently part of conventional medicine.”9
The use of CAM may be prompted by various factors that eventu-
ally direct cancer patients towards CAM. Emotional impact of
cancer diagnosis, fear of side effects due to conventional therapies,
lack of communication with doctors, and the need of personal
control are among the factors associated with CAM use.10,11 Despite
the fact that CAM is used by an increasing number of Malaysians,rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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effectiveness of CAM over conventional therapies, source of infor-
mation, and disclosure of CAM to the health care providers. This
cross-sectional study aimed to determine the use of CAM among
cancer patients, sources from where CAM related information is
retrieved and CAM disclosure to the health care providers. At the
same time evaluating numerous traditional therapies speciﬁc to
Malaysian culture would be valuable to inform future research
priorities.
2. Methods
2.1. Design and settings
The study was designed as a questionnaire based, cross-
sectional analysis. A prevalence based sample of 393 cancer pa-
tients12 attending the oncology ward at Penang General Hospital,
Penang, Malaysia was hereby selected for the study. Adult patients
(age > 18 years), having been diagnosed with cancer (any type) at
least 6 months ago and not > 5 years postdiagnosis, able to read or
understand Malay (national language of Malaysia) or the English
language were recruited for 4 months. The survey questionnaire
with a cover letter explaining the aims of the study was used for
data collection. Each participant was asked to ﬁll in a consent form
prior to responding to the survey questionnaire. Each participant
was asked, “Have you ever used CAM for your cancer?” This
question was considered as a screening question. Participants were
than instructed verbally to follow the instructions on the ques-
tionnaire. The contents of the cover letter assured patients that
refusal to participate in the study or information regarding the CAM
use will not be disclosed to their physicians.
2.2. Ethical approval
Ethical approval was obtained by the Medical Research Ethics
Committee, Ministry of Health, Malaysia.
2.3. Study tool development
For an in depth and rational analysis, two qualitative studies
exploring patients' beliefs towards cancer, treatment seeking
behavior, perceptions towards CAM effectiveness for cancer, and
reasons of CAM use13,14 were undertaken prior to the commence-
ment of the current study. The study questionnaire was thus con-
structed by the research team through an extensive literature
review and results from the qualitative phases.15e17 However, the
biggest challenge faced by the research team was in acquiring a
complete and well deﬁned list of CAM used in cancer. CAM is a very
broad term and getting patients' response for each CAM was
exhausting and time consuming. Therefore, a simple list of CAM
modalities were provided in the questionnaire; however, patients
were given the opportunity to add in any “out of the list” CAM
during the study. The ﬁnal questionnaire was comprised of de-
mographic and disease characteristics, monthly CAM expenditure
and CAM recommendations, and CAM disclosure to the doctors.
The study questionnaire was initially developed in English. Since
the Malay language is widely spoken by Malaysians, the ques-
tionnaire was than translated into Malay language by using stan-
dard translation procedure.18 The face and content validity of the
questionnaire was established by experts from School of Pharma-
ceutical Sciences, Universiti Sains Malaysia. Internal consistency
was assessed by using Cronbach a (a ¼ 0.7) and was found to be in
acceptable ranges.19 The contents, clarity of language, ease of
administration, and appropriateness of the items in line with the
study's objectives were assessed prior to the pilot study. The studyquestionnaire was piloted among 20 cancer patients for its
acceptability and consistency. Little modiﬁcation in the question-
naire was needed after the pilot study. Data from the pilot study
was not added to the ﬁnal analysis. As the consistency and validity
of the study questionnairewas stabilized, the instrument wasmade
available for data collection.
2.4. Measures
The study questionnaire comprised four sections including de-
mographics and disease characteristics, details of CAM use, source
of CAM information, and disclosure of CAM to the doctors. CAM
users were deﬁned as patients continually using at least one form of
CAM therapy for at least 1 month after the diagnosis of cancer.
2.5. Data analysis
Descriptive statistics were used for types of CAM, prevalence of
CAM use, and CAM disclosure to the doctors. Chi-square test was
applied to estimate the association among independent study
variables and CAM utilization. For all statistical analysis, p < 0.05
was considered as signiﬁcant. Data were analyzed by using SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic and disease characteristics
The mean age± standard deviation of the respondents was
53.92 ± 13.0 years. Of these respondents, the cohort was dominated
by women 254 (64.6%). Respondents were split between Malay 190
(48.3%), Chinese 136 (34.6%), and Indian 60 (15.3%) ethnic groups.
The demographic and disease related characteristics of the study
participants are summarized in Table 1. Only 82 (20.9%) patients
reported having a private medical insurance. All of the study par-
ticipants were receiving treatments in government hospitals where
most of the treatment are provided free of charge. The top three
primary cancer sites were breast cancer, gastrointestinal cancers
(colon, rectum, stomach, and intestine) and gynecological cancers
(ovarian, cervical, uterine etc.). A total of 268 (68.18%) participants
reported their cancer stage to be between slightly advanced to very
advance at the time of interview. In addition 134 (34%) received
chemotherapy, surgery, and radiotherapy; 67 (17%) received sur-
gery and chemotherapy; and 57 (14.5%) were on chemotherapy
alone. Among all the demographic variables, CAM usage was
signiﬁcantly associated with gender (p ¼ 0.021) level of education
(p ¼ 0.001), employment status (p ¼ 0.02), and monthly income
(p < 0.001).
3.2. CAM use
Out of 393 respondents, 184 (46.1%) had used CAM for their
condition. More than half of the CAM users 126 (68.5%) were
actively reported to use one or more types of CAM at the time of
interview. The number of CAM therapies used by the participants
ranged from a minimum of one to a maximum of eight therapies at
one time. Beside patients' own initiative [33 (17.9%) patients] to
search and decide to use speciﬁc CAM, friends and family members
were among the most important sources of information for CAM,
[139 (75.5%) patients]. Only 21 (11.4%) patients reported that they
obtained information from the oncologists regarding CAM. An
estimation of monthly expenditure and sources of information on
CAM is summarized in Table 2. When asked about any side effects
suffered due to CAM therapies only 24 (13%) patients reported
“yes”, and 145 (78.8%) patients reported “no”, while 15 (8.2%)
Table 1
Demographic and disease characteristics of the participants.
Variables CAM users
n ¼ 184
CAM nonusers
n ¼ 209
c2 p
n (%) n (%)
Age (y), mean ± SD ¼ 53.92 ± 13.0
18e27
28e37 7 (3.8) 5 (2.3) 0.383
38e47 13 (7.0) 16 (7.6)
48e57 38 (20.6) 35 (16.7)
58e67 57 (30.9) 61 (29.1)
68e77 53 (28.8) 56 (26.7)
78e88 16 (8.6) 36 (17.2)
Gender
Male 52 (28.2) 82 (40.1) 0.021
Female 132 (71.7) 128 (59.8)
Race
Malay 91 (49.4) 99 (47.3) 0.127
Chinese 70 (38.0) 66 (31.5)
Indian 20 (10.8) 40 (19.1)
Others 3 (1.6) 4 (1.9)
Religion
Islam 94 (51.0) 100 (47.8) 0.051
Buddhism 62 (33.6) 63 (30.1)
Hinduism 16 (8.6) 36 (17.2)
Christianity 10 (5.4) 4 (1.9)
Others 1 (0.5) 3 (1.4)
Atheist 1 (0.5) 3 (1.4)
Educational status
Primary 42 (22.8) 71 (33.9) 0.001
Secondary 91 (49.4) 100 (47.8)
Diploma/matriculation 19 (10.3) 9 (4.3)
University degree 17 (9.2) 5 (2.3)
Postgraduate degree 3 (1.6) 2 (0.9)
Never go to school 12 (6.5) 22 (10.5)
Marital status
Unmarried 19 (10.3) 22 (10.5) 0.549
Married 155 (84.2) 170 (81.3)
Divorced 4 (2.17) 3 (1.4)
Widowed 6 (3.2) 13 (6.2)
Others 0 (0) 1 (0.4)
Employment status
Employed 60 (32.6) 45 (21.5) 0.021
Unemployed 43 (23.3) 76 (36.3)
Retired 38 (20.6) 36 (17.2)
Home maker 39 (21.1) 48 (22.9)
Student 2 (1.0) 4 (1.9)
Others 2 (1.0) 0 (0)
Monthly income in MYR/month
No income 95 (51.6) 155 (74.1) <0.001
< 1000 29 (15.7) 27 (12.9)
1000e3000 40 (21.7) 24 (11.4)
> 3000 20 (10.8) 3 (1.4)
Primary cancer site
Don't know 0 (0) 2 (0.9) 0.245
Breast 79 (42.9) 64 (30.6)
GIT cancersa 38 (20.6) 50 (23.9)
Gynaecological cancersb 16 (8.6) 21 (10.0)
Lung 13 (7.0) 21 (10.0)
Nasopharynx 12 (6.5) 11 (5.2)
Prostate gland 7 (3.8) 8 (3.8)
Thyroid 3 (1.6) 5 (2.3)
Othersc 16 (8.6) 27 (12.9)
Duration of disease (y), mean ± SD ¼ 2.0 ± 0.89
0.5e1 63 (34.2) 84 (40.1) 0.147
1e3 66 (35.8) 83 (39.7)
3e5 43 (23.3) 31 (14.8)
Don't know/not sure 12 (6.5) 11 (5.2)
Cancer stage
Very advanced 52 (32.6) 41 (20.5) 0.051
Slightly advanced 85 (38.5) 101 (44.9)
Table 1 (continued )
Variables CAM users
n ¼ 184
CAM nonusers
n ¼ 209
c2 p
n (%) n (%)
Not advanced at all 31 (16.3) 34 (16.7)
Undetermined 8 (4.3) 14 (6.2)
Don't know/not sure 8 (4.3) 19 (11.4)
CAM ¼ complementary and alternative medicines; SD ¼ standard deviation.
a Gastrointestinal tract cancers include colon, rectum, stomach, and intestine.
b Gynaecological cancers include cervix, uterine and ovarian cancers.
c Other cancer sites include carcinoma of tongue, germ cell, skin, bone, brain, and
lymphoma.
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CAM therapies or the conventional therapies, or are the symptoms
of cancer itself. The nature and severity of side effects due to CAM
were not recorded, so no inferential conclusion can be made on
potential harmful effects of speciﬁc CAM therapies on cancer
patients.
3.3. Types of CAM used by study participants
Nutritional supplements (n¼ 77, 41.8%), herbal products (n¼ 74,
40.2%) and multivitamin (n ¼ 62, 33.6%) were the most frequent
CAM used by the patients. The types of CAM utilized by the study
participants are summarized in Table 3. Among herbs, Sabah snake
grass (Clinathanus nutans), and betel nut (Areca catechu)/betel leaf
(Piper betle) were identiﬁed the most common herbs used by the
participants. Prayers for health reasons were used by 51 (27.7%)
patients. However, 20 (10.8%) respondents reported visiting spiri-
tual or religious healers as CAM.
3.4. Disclosure of CAM use to oncologists
Although CAM disclosure rate was 43%, only 62 (33.7%) of the
respondents reported that their doctors had speciﬁcally asked
about CAM use. The reasons of CAM disclosure and response of
doctors upon CAM disclosure are summarized in Table 4. The most
common reason given for nondisclosure by the respondents was “itTable 2
Monthly complementary and alternative medicine (CAM)
expenditure and source of information (n ¼ 184).
n ¼ 184
n (%)
Monthly expenditure on CAM in MYR
< 50 18 (9.8)
50e100 26 (14.1)
101e500 43 (23.4)
501e1000 13 (7.1)
> 1000 4 (2.2)
Not sure 80 (43.5)
Sources of information about CAMa
Friends or family 139 (75.5)
Own free will 33 (17.9)
Mass media 23 (12.5)
Health care providers 21 (11.4)
Cancer survivors 13 (2.2)
CAM vendors 4 (7.9)
MYR ¼ Malaysian Ringgit.
a Total percentagemay not be 100% due to the choice given for
multiple responses.
Table 4
CAM disclosure to the health care providers.
Variables n (%)
Did your doctors asked you about your CAM use? (n ¼ 184)
Yes 62 (33.7)
No 117 (63.6)
Not sure 5 (2.7)
Did you disclose your CAM use to your doctors? (n ¼ 184)
Yes 79 (43)
No 105 (57.1)
How did you doctor respond upon your CAM disclosure? (n ¼ 79)
Agreed of CAM use 28 (35.4)
Disagreed of CAM use 15 (18.9)
Neutral about CAM use 36 (45.5)
Most important reasons of CAM non-disclosure (n ¼ 105)
Not important for doctors to know about CAM use 67 (63.8)
They never ask, I never tell 15 (14.2)
Doctors have little knowledge about CAM 9 (8.5)
Fear of CAM use disapproval by the doctors 8 (7.6)
Fear of termination of conventional therapies 6 (5.7)
Table 3
Types of complementary and alternative medicines (CAM) utilized by the study
participants.a
CAM categories n ¼ 184
n (%)
Biologically based therapies
Nutritional supplements (vitamins, mineral, enzymes) 134 (72.8)
Special diet (herbs, animal products, juices)
Mindebody medicines
Prayers for health reasons/spirituality 75 (40.8)
Others (meditation, T'ai chi (太極拳 tai jí quan), music,
yoga, Qigong (氣功 qì gong),
hypnotherapy, Reiki)
Whole medical system
Traditional Chinese medicine (中醫 zhong yı; TCM) 68 (36.9)
Traditional Malay therapies
Homeopathy
Ayurveda
Energy medicines
Light therapy, Ozone therapy 3 (1.6)
Manipulative and body-based therapies
Massage, herbal baths (藥浴 yao yù)/aromatherapy 2 (1.0)
a Total percentage may not be 100% due to the choice given for multiple
responses.
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34.2 %).4. Discussion
The purpose of this study was to discern the pattern of CAM use
among Malaysian cancer patients. About 46.1% of the participants
reported using CAMwhich is similar towhat has been found among
cancer patients in other studies.20,21 Although there are studies that
have reported a prevalence that is double the ﬁgure reported in this
study,7,22 this could be due to a difference of study instrument (e.g.,
differences in the classiﬁcation of CAM) and the study sample. The
majority of participants were diagnosed with cancer during 2011:
perhaps they may not have had enough opportunity or time to
think about CAM use. Keeping this limitation in mind, the per-
centage of CAM use may change if the same patients are inter-
viewed after 1 year or 2 years.
From our sample, female breast cancer patients were the
highest among CAM users. Monthly income, employment, and
educational status were signiﬁcantly associated with CAM use in
the current study. These results are in accordance to what was re-
ported from previous studies.17e19 Although no signiﬁcant associ-
ation was found between the stage of cancer and CAM use, thepercentage use of CAM was high among patients who had more
advanced disease. This may be explained by the fact that patients at
the terminal stages are often desperate to survive and usually try
every possible method available to cure the cancer.23 Several
studies have reported patients of Malay ethnicity amongst the
highest of CAM for cancer3,4; however, no signiﬁcant association
was found between ethnicity and CAM use, although female Malay
patients reported the highest CAM usage for cancer.
Vitamins and dietary supplements were themost frequent types
of CAM used by the study participants. The majority of them were
using megavitamin and health supplements such as “ﬁt for life”,
MegaV, etc. Cancer patients reported to utilize vitamin and health
supplements to reduce cancer symptoms, unwanted effects of
chemotherapies such as anemia, and for healthmaintenance.22,24,25
Chemotherapy induced anemia and its impact on cancer patients'
quality of life have been studied previously.26,27 Blood transfusion
and epoietin are among the few remedies to reduce the effects of
chemotherapy on patients' hemoglobin (Hb) levels28; however, the
potential dangers of blood transfusion are important to consider
prior to making decisions. In such condition, use of multivitamin
and food supplements rich in iron contents may beneﬁt cancer
patients to reduce chemotherapy-induced side effects, in particular
low Hb levels. Patients can be encouraged to use products with
proven efﬁcacy to improve Hb levels. At the same time patients
should be reminded that these supplements do not guaranties a
cure to cancer. During the past decade, enforcement activities
conducted by the Traditional and Complementary Medicine divi-
sion, of the Malaysian Ministry of Health have reported that false
claims have been made on numerous CAM therapies available in
Malaysian markets.29 As the majority of CAM users perceived CAM
to be an effective agent to cure cancer, it is important to ensure the
validity and reliability of the claims made by the manufacturers.
At present herbal products are gaining popularity in the treat-
ment and prevention of various diseases. Speciﬁc to cancer, studies
reported that herbal products are mainly used to slow down the
disease progression and to relive symptoms.30,31 Similarly,
numerous local herbs such as Sabah snake grass (C. nutans), betel
nut (A. catechu), betel leaf (P. betle) were used by the study par-
ticipants. For example, Sabah snake grass abundantly grows in
Malaysia and local traditions claims a cure to cancer.32,33 However,
this Thai medicinal plant is well documented for its anti-inﬂam-
matory34 actions as well as activities against herpes virus.35
Abundant use of this plant by Malaysian cancer patients may
offer opportunities to ethnopharmacology researchers to evaluate
the efﬁcacy and safety of this herb for cancer.
There is a growing interest towards the beneﬁcial effects of
mind body therapies such as meditation, yoga, and faith-healing
practices to relieve symptoms such as anxiety, emotional distress,
nausea, and pain, and to rejuvenate mentally.36 Prayers for health
reasons are not commonly included as CAM therapies; however,
studies that have categorized prayers as CAM have shown a higher
percentage of CAM use among cancer patients.37,38 The inclusion of
spiritual practices as CAM may reﬂect either spiritual beliefs to-
wards the causes of cancer or the easy access to spiritual therapies
with minimal cost or both.14,39 The emotional impact of a cancer
diagnosis, uncertainty, and fear of death may lead patients to turn
to spiritual help as a way of coping or to derive comfort. Malaysian
policy on integrative medicines encourages the use of noninvasive
mind body soul therapies such as hypnotherapy and psychotherapy
therapies to help patients cope with the psychological effects of
cancer.29 To date, nine government hospitals all over the country
offer traditional and complementary therapies to the patients with
chronic diseases including cancer. Despite oncologists' negative
attitude towards CAM, it is evident that some of the CAM therapies
such as acupuncture, chiropractic, and massage therapies receive
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ever, oncologists' perceptions towards CAM integration have never
been evaluated in Malaysian culture. There is an immediate need to
evaluate health care workers' use and attitude to CAM in Malaysia
to support government efforts towards integrative medicines.
As reported previously, friends and family members were the
common source of receiving advice and recommendations about
CAM among the study participants.42 Although health care pro-
viders should be the most preferable source of information
regarding CAM.43,44 only a few participants reported seeking advice
from them. The physicians' willingness to talk about CAM, and their
readiness to respond to patients' queries regarding CAM have yet to
be evaluated inMalaysia. CAM disclosure rate in this studywas 43%,
which is slightly higher than what was reported previously.45 The
reason of nondisclosure highlights the lack of importance placed on
the physicians' role in dealing with CAM as only in very few cases
did the physician initiate the dialogue of CAM use. It also indicates
patients' lack of knowledge regarding harmful interactions of CAM
with conventional therapies. This could indicate that there may be
inadequate information available about CAM for Malaysian health
care providers. A reluctance to discuss CAM openly with patients
can result in a less than optimal health care delivery because in-
teractions between CAM and conventional therapies may be
missed.
4.1. Limitations
The study has some limitations. It focused on patients already
receiving conventional treatment for cancer. Investigating preva-
lence of CAM use among patients who have decided to forgo con-
ventional therapies in favor of CAM may highlight different issues
regarding perceived effectiveness of CAM and conventional thera-
pies. Furthermore, the study was conducted in one hospital of
Penang state and further research is required to generalize the
ﬁndings to the entire Malaysian population. The results are sub-
jected to recall bias for CAM use and its disclosure to the health care
providers.
5. Conclusion
This study conﬁrmed that CAM use is common among Malay-
sian cancer patients thus highlighting a greater need of patient
education regarding CAM therapies and their potential interactions
with biomedical treatment. The results also identiﬁed some local
herbs claimed to cure cancer, which opens the platform to more
research and investigation to prove the safety and efﬁcacy of these
herbs to cure cancer. Reasons of CAM nondisclosure to the health
care providers demands a need to promote an open nonjudgmental
discussion by the health care professionals. Health care providers
must be aware of patients' concerns regarding CAM.
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